Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Vaccine ; 29(47): 8719-30, 2011 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-21864616

RESUMEN

Bovine respiratory syncytial virus (BRSV) is a major cause of bronchiolitis and pneumonia in cattle and causes yearly outbreaks with high morbidity in Europe. Commercial vaccines against this virus needs improvement of efficacy, especially in calves with BRSV-specific maternally derived antibodies (MDA). We previously reported that an experimental BRSV-ISCOM vaccine, but not a commercial vaccine, induced strong clinical and virological protection in calves with MDA, immunized at 7-15 weeks of age. The aim of the present study was to characterize the immune responses, as well as to investigate the efficacy and safety in younger animals, representing the target population for vaccination. Four groups of five 3-8 week old calves with variable levels of BRSV-specific MDA were immunized s.c. twice at a 3 weeks interval with (i) BRSV immunostimulating complexes (BRSV-ISCOMs), (ii) BRSV-protein, (iii) adjuvant, or (iv) PBS. All calves were challenged with virulent BRSV by aerosol 2 weeks later and euthanized on day 6 after infection. The cellular and humoral responses were monitored as well as the clinical signs, the viral excretion and the pathology following challenge. Despite presence of MDA at the time of the immunization, only a minimum of clinical signs were observed in the BRSV-ISCOM group after challenge. In contrast, in all control groups, clinical signs of disease were observed in most of the animals (respiratory rates up to 76min(-1) and rectal temperatures up to 41°C). The clinical protection was associated to a highly significant reduction of virus replication in the upper and lower respiratory tract of calves, rapid systemic and local antibody responses and T helper cell responses dominated by IFNγ production. Animals that did not shed virus detectable by PCR or cell culture following challenge possessed particularly high levels of pulmonary IgA. The protective immunological responses to BRSV proteins and the ability to overcome the inhibiting effect of MDA were dependent on ISCOM borne antigen presentation.


Asunto(s)
Enfermedades de los Bovinos/prevención & control , Portadores de Fármacos/administración & dosificación , ISCOMs/administración & dosificación , Infecciones por Virus Sincitial Respiratorio/veterinaria , Virus Sincitial Respiratorio Bovino/inmunología , Vacunas Virales/efectos adversos , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/sangre , Bronquiolitis/patología , Bronquiolitis/prevención & control , Bronquiolitis/veterinaria , Bovinos , Enfermedades de los Bovinos/patología , Europa (Continente) , Inmunización Secundaria/métodos , Inmunoglobulina A/análisis , Inmunoglobulina G/sangre , Inyecciones Subcutáneas , Leucocitos Mononucleares/inmunología , Neumonía Viral/patología , Neumonía Viral/prevención & control , Neumonía Viral/veterinaria , Infecciones por Virus Sincitial Respiratorio/patología , Infecciones por Virus Sincitial Respiratorio/prevención & control , Sistema Respiratorio/inmunología , Sistema Respiratorio/patología , Sistema Respiratorio/virología , Índice de Severidad de la Enfermedad , Vacunación/métodos , Vacunas Virales/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA